와이바이오로직스

338840KOSDAQ자연과학 및 공학 연구개발업

41.0 / 100

Reference Date: 2026-04-13

Financial Score10.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Declined 11.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

WaiBioLogics is a biopharmaceutical company developing advanced antibody-based therapies, including immune checkpoint inhibitors, ADCs, and bispecific antibodies, leveraging its proprietary discovery platform. Key pipelines include YBL-006, AR166, AR169, and AR170, with revenue generated through technology licensing and contract research services.

Number of Employees

58people

Average Salary

60.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

14.52Industry Average 3.820.0Point

3.8x industry avg (risky)

ROE

-186.97Industry Average -32.113.5Point

5.8x industry avg (excellent)

Debt Ratio

105.13Industry Average 7.520.0Point

14.0x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.1% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲3.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -111.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
[애프터마켓 브리핑] 오후 국제 유가 재상승…코스피 상승폭 축소
국내 증시가 엔비디아 GTC와 유가 하락에 힘입어 상승 출발했으나, 국제 유가 재상승으로 상승폭이 축소되었다는 내용으로, 와이바이오로직스와 직접적인 관련은 없습니다.

Detailed Momentum

52-week position6.0Point

52w upper range (64%)

Current 25,450Won52-week high 35,60052-week low 6,950

1-month return1.0Point

1m -11.17% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0

Neutral주식매수선택권행사2026-04-09
Neutral주주명부폐쇄기간또는기준일설정2026-04-06
Neutral정기주주총회결과2026-03-31
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral감사보고서제출2026-03-23